HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.

Abstract
Nitric oxide (NO) has been implicated as a potential causative factor for endogenous p53 mutations in gastrointestinal malignancy. To investigate the role of NO in esophageal adenocarcinoma (EADC), we studied patterns of p53 mutations, expression of inducible nitric oxide synthase (iNOS) and the tissue accumulation of nitrotyrosine (NTS), a stable reaction product of NO and a marker for cellular protein damage, in human premalignant and malignant esophageal epithelia. Tissues were obtained from patients with gastroesophageal reflux disease (GERD)-induced esophagitis (n = 76), Barrett's esophagus (BE; n = 119) and primary EADC (n = 54). DNA sequencing was used to characterize p53 mutations, RT-PCR to study iNOS mRNA expression, and immunohistochemistry to study NTS. Relative to self-matched normal epithelia, a progressive increase in iNOS mRNA expression was seen in GERD (30%; 23/76), BE (48%; 57/119), and EADC (63%; 34/54) tissues (P < 0.001). Among patients with EADC, elevated levels of NTS immunoreactivity were more frequent in tumors with p53 mutations (11/21; 52%) compared with tumors with wild-type p53 (9/33; 27%; P = 0.063), and specifically in tumors with p53 mutations at CpG dinucleotides (10/12; 83%) compared with non-CpG p53 mutations (1/9; 11%; P = 0.008). The increasing frequency of iNOS (mRNA) overexpression in GERD, BE and EADC supports the hypothesis that an active inflammatory process, most likely a consequence of GERD, underlies molecular progression to EADC. The highly significant association between NTS, reflecting chronic NO-induced cellular protein damage, and endogenous p53 mutations at CpG dinucleotides, provides further evidence for a molecular link between chronic inflammation and esophageal malignancy.
AuthorsNadine M Vaninetti, Laurette Geldenhuys, Geoffrey A Porter, Harvey Risch, Pierre Hainaut, Duane L Guernsey, Alan G Casson
JournalMolecular carcinogenesis (Mol Carcinog) Vol. 47 Issue 4 Pg. 275-85 (Apr 2008) ISSN: 1098-2744 [Electronic] United States
PMID17849424 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright(c) 2007 Wiley-Liss, Inc.
Chemical References
  • Inflammation Mediators
  • Tumor Suppressor Protein p53
  • Nitric Oxide
  • 3-nitrotyrosine
  • Tyrosine
  • NOS2 protein, human
  • Nitric Oxide Synthase Type II
Topics
  • Adenocarcinoma (enzymology, etiology, genetics, pathology)
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Barrett Esophagus (enzymology, etiology, genetics, pathology)
  • Chronic Disease
  • Esophageal Neoplasms (enzymology, etiology, genetics, pathology)
  • Female
  • Genes, p53
  • Humans
  • Inflammation Mediators (physiology)
  • Male
  • Middle Aged
  • Nitric Oxide (biosynthesis)
  • Nitric Oxide Synthase Type II (physiology)
  • Point Mutation
  • Tumor Suppressor Protein p53 (genetics)
  • Tyrosine (analogs & derivatives, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: